In short
Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, has announced the completion of enrollment in the Tryton Pivotal IDE trial evaluating the company’s Side Branch Stent.™
Background
In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion, presenting the physician with a time-consuming and technically difficult procedure. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis.
The Tryton Side Branch Stent System is designed and built for bifurcations using proprietary Tri-zone™ technology to offer a dedicated strategy for treating these lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
Physician comments
Martin B. Leon, M.D., F.A.C.C., professor of Medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, and founder and chairman emeritus of the Cardiovascular Research Foundation, serves as principal investigator of the study.
“Completion of patient recruitment is a major milestone for the Tryton IDE Pivotal Trial, which is truly a landmark study. In addition to being the first powered randomised controlled trial evaluating a dedicated side branch stent, it is the largest coronary bifurcation study ever attempted and the first one to have core angiographic (3D and planar) and IVUS sub-studies. The results of the Tryton study will directly guide the treatment of patients with complex bifurcation disease,” said Dr. Leon. “Our current inability to treat these lesions with ‘work horse’ drug eluting stents, represents an important unmet clinical need which confronts interventional cardiologists. From my travels to Europe and Israel, I have been impressed with how easily the Tryton Stent is incorporated into routine practice. We look forward to results from this trial.”
Company comments
“Tryton Medical’s differentiated technology addresses the challenges of bifurcated lesions, which affect nearly a third of patients undergoing a PCI procedure. Data from more than 1,000 registry patients in Europe treated with the Tryton stent are already challenging provisional stenting, with compelling results of target lesion revascularization of four percent and thrombosis of 0.5 percent at one year,” said Shawn P. McCarthy, president and CEO of Tryton Medical. “We are looking to corroborate this positive registry data in the Tryton Medical randomized controlled study. With more than 6,000 implants to date, we are leveraging our impressive data to further expand globally. We are on track to be the first and only approved stent for coronary bifurcations in the U.S.”
Regulatory status
The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.
Source: Tryton Medical, Inc., Business Wire
published: November 27, 2012 in: Cardio, Clinical Studies/Trials